Table 2.
Stage-specific comparison of the sociodemographic and clinical characteristics of patients with SCSTs versus GCTs
| Factor | Stage I | Stage II/III | ||||
|---|---|---|---|---|---|---|
| SCSTs | GCTs | p-value | SCSTs | GCTs | p-value | |
| N | 259 | 32,204 | 21 | 9708 | ||
| Age at diagnosis, median (IQR) | 43 (34, 57) | 34 (28, 43) | < 0.001 | 55 (42, 64) | 33 (26, 42) | < 0.001 |
| Diagnosis year | < 0.001 | 0.38 | ||||
| 2004–2005 | 46 (18%) | 6387 (20%) | 2 (10%) | 1780 (18%) | ||
| 2006–2007 | 33 (13%) | 6416 (20%) | 6 (29%) | 1874 (19%) | ||
| 2008–2009 | 45 (17%) | 6528 (20%) | 5 (24%) | 1942 (20%) | ||
| 2010–2011 | 75 (29%) | 6487 (20%) | 6 (29%) | 1993 (21%) | ||
| 2012–2013 | 60 (23%) | 6386 (20%) | 2 (10%) | 2119 (22%) | ||
| Race/ethnicity | < 0.001 | 0.62 | ||||
| Non-Hispanic White | 157 (61%) | 25,125 (78%) | 17 (81%) | 7266 (75%) | ||
| Non-Hispanic Black | 47 (18%) | 809 (3%) | 1 (5%) | 311 (3%) | ||
| Hispanic/Other | 52 (20%) | 5672 (18%) | 3 (14%) | 2000 (21%) | ||
| Unknown | 3 (1%) | 598 (2%) | 0 (0%) | 131 (1%) | ||
| Insurance | < 0.001 | 0.087 | ||||
| Uninsured | 169 (65%) | 3411 (11%) | 4 (19%) | 1351 (14%) | ||
| Private insurance | 20 (8%) | 24,575 (76%) | 9 (43%) | 6339 (65%) | ||
|
Medicaid/Medicare/other government insurance |
62 (24%) | 3605 (11%) | 8 (38%) | 1812 (19%) | ||
| Unknown | 8 (3%) | 613 (2%) | 0 (0%) | 206 (2%) | ||
| Income (per year) | 0.38 | 0.68 | ||||
| Less than $38 k | 40 (15%) | 3981 (12%) | 5 (24%) | 1507 (16%) | ||
| $38 k-62,999 | 115 (44%) | 15,408 (48%) | 10 (48%) | 4791 (49%) | ||
| $63 k or greater | 100 (39%) | 12,407 (39%) | 6 (29%) | 3256 (34%) | ||
| Unknown | 4 (2%) | 408 (1%) | 0 (0%) | 154 (2%) | ||
| Percent in ZIP code without a high school degree | 0.69 | 0.75 | ||||
| 21% or greater | 37 (14%) | 4450 (14%) | 5 (24%) | 1711 (18%) | ||
| 7–20.9% | 147 (57%) | 17,658 (55%) | 12 (57%) | 5355 (55%) | ||
| Less than 7% | 71 (27%) | 9716 (30%) | 4 (19%) | 2496 (26%) | ||
| Unknown | 4 (2%) | 380 (1%) | 0 (0%) | 146 (2%) | ||
| Residence | 0.42 | 0.51 | ||||
| Metropolitan | 221 (85%) | 26,877 (84%) | 16 (76%) | 7934 (82%) | ||
| Urban/rural | 38 (15%) | 5327 (17%) | 5 (24%) | 1774 (18%) | ||
| Charlson-Deyo comorbidity score | 0.016 | < 0.001 | ||||
| 0 | 237 (92%) | 30,544 (95%) | 15 (71%) | 9029 (93%) | ||
| 1 or more | 22 (9%) | 1660 (5%) | 6 (29%) | 679 (7%) | ||
| Stage | 0.21 | |||||
| Stage I | 259 (100%) | 32,204 (100%) | – | – | ||
| Stage II | – | – | 9 (43%) | 5469 (56%) | ||
| Stage III | – | – | 12 (57%) | 4239 (44%) | ||
| Treatment | < 0.001 | < 0.001 | ||||
| No orchiectomy | 0 (0%) | 30 (0.1%) | 2 (10%) | 634 (7%) | ||
| Orchiectomy alone | 250 (97%) | 16,519 (51%) | 10 (48%) | 1106 (11%) | ||
| Orchiectomy + adjuvant therapy | 9 (4%) | 15,626 (49%) | 9 (43%) | 7941 (82%) | ||
| Other/unknown | 0 (0%) | 29 (0.1%) | 0 (0%) | 27 (0.3%) | ||
| Last contact or death, months from diagnosis, median (IQR) | N = 229 | N = 28,855 | < 0.001 | N = 20 | N = 8612 | 0.002 |
| 41 (22, 62) | 53 (29, 80) | 19 (8, 55) | 47 (24, 75) | |||
| Time from diagnosis to death, median (IQR) | N = 13 | N = 747 | N = 14 | N = 866 | ||
| 23 (18, 43) | 31 (14, 58) | 0.78 | 11 (7, 21) | 13 (4, 28) | 0.96 | |
GCTs Germ cell tumors, IQR Interquartile range, SCSTs Sex cord stromal tumors